CN107462706A - A kind of tumor reagent box - Google Patents
A kind of tumor reagent box Download PDFInfo
- Publication number
- CN107462706A CN107462706A CN201710647826.0A CN201710647826A CN107462706A CN 107462706 A CN107462706 A CN 107462706A CN 201710647826 A CN201710647826 A CN 201710647826A CN 107462706 A CN107462706 A CN 107462706A
- Authority
- CN
- China
- Prior art keywords
- oncoprotein
- monoclonal antibodies
- antibody
- cells
- pbs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of tumor reagent box, including oncoprotein P185 monoclonal antibodies, ELISA Plate, positive reference substance, negative controls, cleaning solution, terminate liquid, the specific antibody of calprotectin (CRT), horseradish peroxidase streptavidin and its chromogenic substrate, described oncoprotein P185 monoclonal antibodies are coated on the oncoprotein P185 monoclonal antibodies of the oncoprotein P185 monoclonal antibodies and biotin labeling on ELISA Plate.The present invention being capable of easy, high flux and to detect the oncoprotein P185 in human serum in high sensitivity horizontal.
Description
Technical field
The present invention relates to a kind of kit, specifically a kind of tumor reagent box.
Background technology
Calprotectin (Calreticulin, CRT) is the ER molecular with various biological function of 46KD sizes
Chaperone, except being distributed in endoplasmic reticulum, there is expression in nucleus, nuclear membrane, cell membrane surface and extracellular matrix, can send out
Wave a variety of biochemical physiological effects.When tumour occurs, the CRT of secretory is in the serum of hepatocarcinoma patient and the urine of bladder cancer patients
All on the rise in liquid, in addition, the research to gynecological tumor such as breast cancer, cervical carcinoma is displayed that compared to normal healthy controls
CRT expression quantity increased；Find the positive patients of CRT often with distant place lymph when studying stomach cancer with immunohistochemical staining
The transfer of knot, the symptom that tumor-microvessel is assembled and five-year survival rate is low.However, due to tumor development mechanism extremely
The present not yet illustrates, therefore the early detection of tumour also becomes more and more important.In the research and clinical practice of tumour, early stage is sent out
Existing, early diagnosis, early treatment are crucial.Tumor markers (TumorMarker, TM) is in cancer screening, diagnosis, judging prognosis
All there is larger practical value with lapsing to, evaluating treatment curative effect and people at highest risk's follow-up observation etc..As monoclonal resists
The continuous maturation of body technique, there is the monoclonal antibody of substantial amounts of antitumor mark, and examined with special sensitive immunology
Survey technology (RIA, IRMA, ELISA, CLIA, IFA, TRFIA etc.) is combined, and has developed numerous tumor markers detection projects
And constantly it is applied to clinic, it has also become an important Index for examination of tumor patient.Based on above result of study, the present invention will
CRT is selected to carry out the foundation and clinical test of methodology as tumor markers.The present invention using a pair specific monoclonal antibodies and
The more anti-ELISA kit for establishing hypersensitivity, detected for clinical tumor patient and normal healthy controls change of serum C RT.It was found that
CRT levels in affinity antibody to SpA are apparently higher than normal control.
The content of the invention
It is an object of the invention to provide a kind of tumor reagent box, to solve the problems mentioned in the above background technology.
To achieve the above object, the present invention provides following technical scheme：
A kind of tumor reagent box, including oncoprotein P185 monoclonal antibodies, ELISA Plate, positive reference substance, negative control
Product, cleaning solution, terminate liquid, the specific antibody of calprotectin (CRT), horseradish peroxidase-streptavidin and its colour developing bottom
Thing, described oncoprotein P185 monoclonal antibodies are coated on oncoprotein P185 monoclonal antibodies and life on ELISA Plate
The oncoprotein P185 monoclonal antibodies of thing element mark.
As the further scheme of the present invention：The specific antibody is the list by being obtained using calprotectin as immunogene
Clonal antibody and/or polyclonal antibody.
As the further scheme of the present invention：The described oncoprotein P185 monoclonal antibodies being coated on ELISA Plate are
Oncoprotein P185 monoclonal antibodies 2D11, the oncoprotein P185 monoclonal antibodies of described biotin labeling are oncoprotein
P185 monoclonal antibody 3F9, the preparation process of oncoprotein P185 monoclonal antibodies 2D11,3F9 are as follows：A) it is thin with NIH/3T3
First Balb/C female mice of 6~8 weeks is immunized in born of the same parents i.p, obtains the anti-NIH/3T3 serum of female mice；B) collect long to the T6- converged
17 cells, washed 1 time with PBS, by the anti-NIH/3T3 antiserums PBS of above-mentioned preparation with 1:200 dilutions, so
After take 1ml to add in T6-17 cells, be incubated overnight under the conditions of 8 DEG C, during which rock the test tube 5~6 times for holding T6-17 cells,
Then washed 1 time with PBS again, obtain being suspended in the T6-17 cells in PBS；C) PBS bufferings are suspended in above-mentioned
The second batch BaLb/C female mices of 6-8 weeks are immunized in T6-17 cells i.p in liquid, then take the splenocyte of female mice that cell suspension is made；
D) hybridoma of secreting tumor albumen P185 monoclonal antibodies is filtered out from above-mentioned cell suspension with ELISA method, and it is right
Hybridoma carries out cloning, so as to obtain two plants of hybridization with stably excreting oncoprotein P185 monoclonal antibody abilities
Tumor cell strain, it is respectively designated as hybridoma cell strain 2D11, hybridoma cell strain 3F9；E) by hybridoma cell strain 2D11,3F9
It is injected separately into different female mice bodies, collects ascites, by the antibody purification in ascites, produce oncoprotein P185 monoclonal antibodies
2D11、3F9。
As further scheme of the invention：Described cleaning solution is Na2HPO412H2O, 50g by 10g
NaCl, 5g NaH2PO42H2O add purified water dissolving and are settled to obtained by 5000ml.
Compared with prior art, the beneficial effects of the invention are as follows：The present invention easy, high flux and can examine in high sensitivity
The oncoprotein P185 surveyed in human serum is horizontal.
Embodiment
The technical scheme in the embodiment of the present invention is clearly and completely described below, it is clear that described embodiment
Only part of the embodiment of the present invention, rather than whole embodiments.Based on the embodiment in the present invention, the common skill in this area
The every other embodiment that art personnel are obtained under the premise of creative work is not made, belong to the model that the present invention protects
Enclose.
In the embodiment of the present invention, a kind of tumor reagent box, including oncoprotein P185 monoclonal antibodies, ELISA Plate, the positive
Reference substance, negative controls, cleaning solution, terminate liquid, the specific antibody of calprotectin (CRT), horseradish peroxidase-chain parent
The oncoprotein P185 on ELISA Plate is coated on element and its chromogenic substrate, described oncoprotein P185 monoclonal antibodies
The oncoprotein P185 monoclonal antibodies of monoclonal antibody and biotin labeling.The specific antibody is by with calprotectin
The monoclonal antibody and/or polyclonal antibody obtained for immunogene.The described oncoprotein P185 being coated on ELISA Plate is mono-
Clonal antibody is oncoprotein P185 monoclonal antibodies 2D11, the oncoprotein P185 monoclonal antibodies of described biotin labeling
It is as follows for oncoprotein P185 monoclonal antibody 3F9, the preparation process of oncoprotein P185 monoclonal antibodies 2D11,3F9：A) with
First Balb/C female mice of 6~8 weeks is immunized in NIH/3T3 cells i.p, obtains the anti-NIH/3T3 serum of female mice；B) collect long extremely
The T6-17 cells converged, washed 1 time with PBS, by the anti-NIH/3T3 antiserums PBS of above-mentioned preparation with 1:
200 dilutions, then take 1ml to add in T6-17 cells, are incubated overnight under the conditions of 8 DEG C, during which rock and hold T6-17 cells
Test tube 5~6 times, then washed 1 time with PBS again, obtain being suspended in the T6-17 cells in PBS；C) with above-mentioned outstanding
The second batch BaLb/C female mices of 6-8 weeks are immunized in the T6-17 cells i.p floated in PBS, then take the splenocyte system of female mice
Into cell suspension；D) hybridization of secreting tumor albumen P185 monoclonal antibodies is filtered out from above-mentioned cell suspension with ELISA method
Oncocyte, and cloning is carried out to hybridoma, so as to obtain two plants there is stably excreting oncoprotein P185 monoclonals to resist
The hybridoma cell strain of ability of immigrants, it is respectively designated as hybridoma cell strain 2D11, hybridoma cell strain 3F9；E) it is hybridoma is thin
Born of the same parents' strain 2D11,3F9 are injected separately into different female mice bodies, are collected ascites, by the antibody purification in ascites, are produced oncoprotein
P185 monoclonal antibodies 2D11,3F9.Described cleaning solution is by 10g Na2HPO412H2O, 50g NaCl, 5g
NaH2PO42H2O adds purified water dissolving and is settled to obtained by 5000ml.
Embodiment 1：A kind of tumor reagent box, including oncoprotein P185 monoclonal antibodies, ELISA Plate, positive reference substance,
Negative controls, cleaning solution, terminate liquid, the specific antibody of calprotectin (CRT), horseradish peroxidase-streptavidin and
Its chromogenic substrate, described oncoprotein P185 monoclonal antibodies are coated on the oncoprotein P185 monoclonals on ELISA Plate
The oncoprotein P185 monoclonal antibodies of antibody and biotin labeling.The specific antibody is by using calprotectin to be immune
The monoclonal antibody and/or polyclonal antibody that original obtains.The described oncoprotein P185 monoclonals being coated on ELISA Plate resist
Body is oncoprotein P185 monoclonal antibodies 2D11, and the oncoprotein P185 monoclonal antibodies of described biotin labeling are tumour
Albumen P185 monoclonal antibody 3F9, the preparation process of oncoprotein P185 monoclonal antibodies 2D11,3F9 are as follows：A) with NIH/
First Balb/C female mice of 6~8 weeks is immunized in 3T3 cells i.p, obtains the anti-NIH/3T3 serum of female mice；B) collect long to converging
T6-17 cells, washed 1 time with PBS, by the anti-NIH/3T3 antiserums PBS of above-mentioned preparation with 1:200 is dilute
Release, then take 1ml to add in T6-17 cells, be incubated overnight under the conditions of 8 DEG C, during which rock the test tube 5 for holding T6-17 cells:
It is secondary, then washed 1 time with PBS again, obtain being suspended in the T6-17 cells in PBS；C) it is suspended in PBS with above-mentioned
The second batch BaLb/C female mices of 6-8 weeks are immunized in T6-17 cells i.p in buffer solution, then take the splenocyte of female mice that cell is made
Suspension；D) hybridoma of secreting tumor albumen P185 monoclonal antibodies is filtered out from above-mentioned cell suspension with ELISA method,
And cloning is carried out to hybridoma, there is stably excreting oncoprotein P185 monoclonal antibody abilities so as to obtain two plants
Hybridoma cell strain, it is respectively designated as hybridoma cell strain 2D11, hybridoma cell strain 3F9；E) by hybridoma cell strain 2D11,
3F9 is injected separately into different female mice bodies, is collected ascites, by the antibody purification in ascites, is produced oncoprotein P185 monoclonals
Antibody 2D11,3F9.Described cleaning solution is by 10g Na2HPO412H2O, 50g NaCl, 5g NaH2PO42H2O
Purified water dissolving is added to be settled to obtained by 5000ml.
Embodiment 2：A kind of tumor reagent box, including oncoprotein P185 monoclonal antibodies, ELISA Plate, positive reference substance,
Negative controls, cleaning solution, terminate liquid, the specific antibody of calprotectin (CRT), horseradish peroxidase-streptavidin and
Its chromogenic substrate, described oncoprotein P185 monoclonal antibodies are coated on the oncoprotein P185 monoclonals on ELISA Plate
The oncoprotein P185 monoclonal antibodies of antibody and biotin labeling.The specific antibody is by using calprotectin to be immune
The monoclonal antibody and/or polyclonal antibody that original obtains.The described oncoprotein P185 monoclonals being coated on ELISA Plate resist
Body is oncoprotein P185 monoclonal antibodies 2D11, and the oncoprotein P185 monoclonal antibodies of described biotin labeling are tumour
Albumen P185 monoclonal antibody 3F9, the preparation process of oncoprotein P185 monoclonal antibodies 2D11,3F9 are as follows：A) with NIH/
First Balb/C female mice of 7 weeks is immunized in 3T3 cells i.p, obtains the anti-NIH/3T3 serum of female mice；B) collect long to converging
T6-17 cells, washed 1 time with PBS, by the anti-NIH/3T3 antiserums PBS of above-mentioned preparation with 1:200 dilutions,
Then take 1ml to add in T6-17 cells, be incubated overnight under the conditions of 8 DEG C, during which rock the test tube 7 times for holding T6-17 cells,
Then washed 1 time with PBS again, obtain being suspended in the T6-17 cells in PBS；C) PBS bufferings are suspended in above-mentioned
The second batch BaLb/C female mices of 7 weeks are immunized in T6-17 cells i.p in liquid, then take the splenocyte of female mice that cell suspension is made；d)
The hybridoma of secreting tumor albumen P185 monoclonal antibodies is filtered out from above-mentioned cell suspension with ELISA method, and to miscellaneous
Oncocyte is handed over to carry out cloning, so as to obtain two plants of hybridomas with stably excreting oncoprotein P185 monoclonal antibody abilities
Cell line, it is respectively designated as hybridoma cell strain 2D11, hybridoma cell strain 3F9；E) hybridoma cell strain 2D11,3F9 are divided
Do not inject in different female mice bodies, collect ascites, by the antibody purification in ascites, produce oncoprotein P185 monoclonal antibodies
2D11、3F9.Described cleaning solution is the NaH2PO42H2O additions by 10g Na2HPO412H2O, 50g NaCl, 5g
Purified water dissolving is settled to obtained by 5000ml.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit requires rather than described above limits, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.Moreover, it will be appreciated that although the present specification is described in terms of embodiments, not each
Embodiment only includes an independent technical scheme, and this narrating mode of specification is only this area for clarity
Technical staff should be using specification as an entirety, and the technical solutions in the various embodiments may also be suitably combined, forms this
The other embodiment that art personnel are appreciated that.
Claims (4)
- A kind of 1. tumor reagent box, it is characterised in that including oncoprotein P185 monoclonal antibodies, ELISA Plate, positive reference substance, Negative controls, cleaning solution, terminate liquid, the specific antibody of calprotectin (CRT), horseradish peroxidase-streptavidin and Its chromogenic substrate, described oncoprotein P185 monoclonal antibodies are coated on the oncoprotein P185 monoclonals on ELISA Plate The oncoprotein P185 monoclonal antibodies of antibody and biotin labeling.
- 2. tumor reagent box according to claim 1, it is characterised in that the specific antibody is by with calprotectin The monoclonal antibody and/or polyclonal antibody obtained for immunogene.
- 3. tumor reagent box according to claim 1, it is characterised in that the described oncoprotein being coated on ELISA Plate P185 monoclonal antibodies are oncoprotein P185 monoclonal antibodies 2D11, the oncoprotein P185 Dan Ke of described biotin labeling Grand antibody is oncoprotein P185 monoclonal antibody 3F9, and the preparation process of oncoprotein P185 monoclonal antibodies 2D11,3F9 is such as Under：A) first Balb/C female mice of 6~8 weeks is immunized with NIH/3T3 cells i.p, obtains the anti-NIH/3T3 serum of female mice；b) Length is collected to the T6-17 cells converged, is washed 1 time with PBS, the anti-NIH/3T3 antiserums of above-mentioned preparation is buffered with PBS Liquid is with 1:200 dilutions, then take 1ml to add in T6-17 cells, are incubated overnight under the conditions of 8 DEG C, during which rock and hold T6-17 The test tube of cell 5~6 times, then washed 1 time with PBS again, obtain being suspended in the T6-17 cells in PBS；C) use The second batch BaLb/C female mices of 6-8 weeks are immunized in the above-mentioned T6-17 cells i.p being suspended in PBS, then take the spleen of female mice Cell suspension is made in cell；D) secreting tumor albumen P185 monoclonal antibodies are filtered out from above-mentioned cell suspension with ELISA method Hybridoma, and to hybridoma carry out cloning, so as to obtain two plants have stably excreting oncoprotein P185 it is mono- The hybridoma cell strain of clonal antibody ability, it is respectively designated as hybridoma cell strain 2D11, hybridoma cell strain 3F9；E) will be miscellaneous Hand over tumor cell strain 2D11,3F9 to be injected separately into different female mice bodies, collect ascites, by the antibody purification in ascites, produce tumour Albumen P185 monoclonal antibodies 2D11,3F9.
- 4. tumor reagent box according to claim 1, it is characterised in that described cleaning solution is the Na2HPO4 by 10g 12H2O, 50g NaCl, 5g NaH2PO42H2O add purified water dissolving and are settled to obtained by 5000ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710647826.0A CN107462706A (en) | 2017-08-01 | 2017-08-01 | A kind of tumor reagent box |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710647826.0A CN107462706A (en) | 2017-08-01 | 2017-08-01 | A kind of tumor reagent box |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107462706A true CN107462706A (en) | 2017-12-12 |
Family
ID=60548059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710647826.0A Pending CN107462706A (en) | 2017-08-01 | 2017-08-01 | A kind of tumor reagent box |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107462706A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103091499A (en) * | 2013-01-23 | 2013-05-08 | 三峡大学 | Preparation and application of tumor marker calreticulin detection kit |
| CN103698536A (en) * | 2013-12-20 | 2014-04-02 | 安徽安科生物工程（集团）股份有限公司 | Oncoprotein P185 detection kit |
| CN105916876A (en) * | 2013-09-16 | 2016-08-31 | 分子医学研究中心责任有限公司 | Mutant calreticulin for the diagnosis of myeloid malignancies |
| CN106526194A (en) * | 2016-08-10 | 2017-03-22 | 四川金域医学检验中心有限公司 | Detection kit of oncoprotein |
-
2017
- 2017-08-01 CN CN201710647826.0A patent/CN107462706A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103091499A (en) * | 2013-01-23 | 2013-05-08 | 三峡大学 | Preparation and application of tumor marker calreticulin detection kit |
| CN105916876A (en) * | 2013-09-16 | 2016-08-31 | 分子医学研究中心责任有限公司 | Mutant calreticulin for the diagnosis of myeloid malignancies |
| CN103698536A (en) * | 2013-12-20 | 2014-04-02 | 安徽安科生物工程（集团）股份有限公司 | Oncoprotein P185 detection kit |
| CN106526194A (en) * | 2016-08-10 | 2017-03-22 | 四川金域医学检验中心有限公司 | Detection kit of oncoprotein |
Non-Patent Citations (2)
| Title |
|---|
| ALEKSANDRA ERIC, ET AL.: "Effects of Humoral Immunity and Calreticulin Overexpression on Postoperative Course in Breast Cancer.", 《PATHOL.ONCOL.RES.》 * |
| SL BOHMAN, ET AL.: "Calreticulin Expression in Breast Cancer: Correlation with Prognostic Factors.", 《MODERN PATHOLOGY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102422159B (en) | Immunological measurement reagent for use in measurement of kl-6 | |
| CN103073642A (en) | CRP monoclonal antibody nanometer latex microsphere composition and preparation process thereof | |
| Henrick et al. | Milk matters: soluble Toll-like receptor 2 (sTLR2) in breast milk significantly inhibits HIV-1 infection and inflammation | |
| CN104628843B (en) | A kind of thyrotropin receptor protein, gene order and its kit | |
| CN104792997B (en) | A kind of HCT's original immunity detection reagent and preparation method and application | |
| CN103941021B (en) | Kit for detecting interleukin-6 and method for detecting interleukin-6 for non-diagnostic purpose | |
| CN102159591A (en) | Monoclonal antibody, and immunoassay using same | |
| CN109387627B (en) | Reagent method for screening and early diagnosis of cancer based on placenta-like chondroitin sulfate A | |
| CN103408664A (en) | A-human CXCL1 monoclonal antibody or fragment thereof | |
| JPH04503600A (en) | Anti-interleukin-1α and -1β monoclonal antibodies, methods for producing the same, and application of the antibodies to detection and treatment of interleukin-1α and -1β | |
| Ráki et al. | Similar responses of intestinal T cells from untreated children and adults with celiac disease to deamidated gluten epitopes | |
| CN102725416A (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| CN103074303A (en) | Hybridoma cell strain generating anti-human NGAL specific monoclonal antibody, monoclonal antibody generated by same and application | |
| Huang et al. | Three-dimensional mapping of hepatic lymphatic vessels and transcriptome profiling of lymphatic endothelial cells in healthy and diseased livers | |
| CN106771247A (en) | A kind of diagnostic kit of the microglobulins of β 2 | |
| CN104558171A (en) | Monoclonal antibody, enzyme linked immunosorbent assay and kit for detecting methyltestosterone | |
| CN107462706A (en) | A kind of tumor reagent box | |
| Groves et al. | The preparation of an ovine monoclonal antibody to progesterone | |
| JP2008100986A (en) | C1q-binding substance, and its use | |
| CN104066749A (en) | Monoclonal antibodies which specifically recognize human liver-carboxylesterase 1, hybridoma cell lines which produce monoclonal antibodies, and uses thereof | |
| Banga-Mboko et al. | An improved radioimmunoassay for measurement of pepsinogen in porcine blood samples | |
| CN106244559B (en) | A kind of hybridoma cell strain that secreting anti-human IL-37b monoclonal antibody, anti-human IL-37b monoclonal antibody and its application | |
| CN110218703A (en) | A kind of antigen-specific b cells screening technique and its application in monoclonal antibody preparation | |
| CN104558176A (en) | Monoclonal antibody, enzyme-linked immunosorbent assay method and kit for detecting androgens | |
| CN100430473C (en) | Hybrid tumor cell strain and its produced human alpha-galactosidase A resisting monoclonal antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171212 |